Takeda Adds Exelixis Arrow To Oncology Quiver
Takeda's acquisition of Japanese rights to Exelixis' lead product fills a gap in the oncology portfolio while adding another piece to the US company's global licensing jigsaw.
You may also be interested in...
Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.
With more deals on earlier-stage platform technologies and compounds, the companies offering such assets need to take a rational approach to pricing – accepting a lot of potential back-end compensation – to get fair value, one analyst says.
Company recruited clinical experts to explain why Phase II CABOSUN should be enough for approval and why a Phase III study is now impractical.